Celdara Medical

Allyon Solutions is an early investor in Celdara Medical, an early stage incubator which builds academic and early stage inventions of the Dartmouth Medical School and converts them into functional corporations ready for Series “A” and “B” financing. Co-founded in 2008 by Jake Reder, Director of New Ventures at the Dartmouth Medical School, Celdara is a platform company that creates value by identifying multiple high potential discoveries as they happen, engaging the right people at the right time, and then eliminating barriers to the commercialization of their technology. Once free of the university environment, the disciplined execution of sound early stage business strategies builds these technologies into high potential start-ups ready for the first round of venture investment. Business risk is dramatically reduced through Celdara’s self-funding “collection of platforms” model.
CEO Jake Reder has built his career working at the early stages of innovation in venture capital, academic and corporate arenas. His co-founder, Michael Fanger, who serves as Celdara’s Chairman and Chair of the Scientific Advisory Board, has founded and led billion dollar biotech businesses. He was the President and Chief Executive Officer of Celldex Therapeutics Inc. (NASDAQ: AVAN), as well as the Founder and Director of Medarex (NASDAQ: MEDX) from its inception in 1987 until 2004. Both founders have consistently demonstrated the ability to identify promising concepts and then build them into high-worth businesses.

Business Model

Celdara proactively identifies promising medical technologies, brings them out of the academic environment and builds them into high-potential businesses using non-dilutive funding. Daughter companies are formed around individual or packaged technologies and are spun out at their “Series A” funding event. Celdara keeps equity in the daughter company, but is then operationally uninvolved. Short-term cash flow is addressed through Celdara’s initial focus on service-based and diagnostic opportunities as well as SBIR grants and other non-dilutive funding.